Advisory Services Network, LLC Biocryst Pharmaceuticals Inc Transaction History

Advisory Services Network, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$4.98 - $6.77 $18,625 - $25,319	3,740 New	3,740 $22,000
Q1 2023 May 17, 2023	BUY	$7.94 - $11.84 $11,910 - $17,760	1,500 Added 46.3%	4,740 $39,000
Q4 2022 Feb 13, 2023	BUY	$10.5 - $14.2 $34,020 - $46,008	3,240 New	3,240 $37,000
Q3 2021 Nov 05, 2021	SELL	$14.21 - $17.65 $68,918 - $85,602	-4,850 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$9.5 - $17.24 $46,075 - $83,613	4,850 New	4,850 $77,000
Q1 2021 May 24, 2021	SELL	$7.37 - $13.61 $42,009 - $77,577	-5,700 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $19,551 - $31,521	5,700 New	5,700 $20,000
Q2 2020 Aug 10, 2020	SELL	$1.9 - $5.61 $10,830 - $31,977	-5,700 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$1.59 - $3.45 $2,703 - $5,865	1,700 Added 42.5%	5,700 $20,000
Q4 2018 Feb 15, 2019	SELL	$6.51 - $9.6 $3,255 - $4,800	-500 Reduced 11.11%	4,000 $32,000
Q2 2018 Jul 27, 2018	SELL	$4.6 - $6.52 $9,200 - $13,040	-2,000 Reduced 30.77%	4,500 $26,000
Q2 2017 Aug 17, 2017	BUY	N/A	6,500	6,500 $36,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.